73 m2) generally precludes donation. The Canadian Council for Donation and Transplantation (2006)29 It is recommended that in the absence of higher quality evidence, it is reasonable to

refer to existing guidelines regarding the assessment and eligibility of potential living kidney donors (e.g. Amsterdam Forum). However, it is recommended that these guidelines not be used as absolute criteria where risk is poorly quantified or uncertain. American Society of Transplantation Position Statement on the Medical Evaluation of Living Kidney Donors (2007)30 Renal focused evaluation to determine the presence of underlying kidney disease in the potential donor should include measurement of GFR (method not specified). CKD Stage 3 or less (defined as 30–59 mL/min per 1.73 m2) will typically exclude a living donor candidate from donating based upon scientific data of medical risk. The Organ Procurement and NVP-LDE225 price Transplantation Network (2008)31 Medical evaluation of potential donors should include: measurement of GFR by 24 h FK866 urine collection or equivalent testing.

Possible exclusion criteria that may make an individual unsuitable for living donation includes: Perform a prospective assessment of donors with respect to the relationship between pre-donation GFR and: (i)  mortality Solomon Cohney has a Level IIb conflict of interest while John Kanellis and Martin Howell have no relevant financial affiliations that would cause a conflict of interest according

to the conflict of interest statement set down by CARI. “
“We investigated the handling of phosphate by end-stage kidneys and the contribution of residual renal function (RRF) to phosphate homeostasis in haemodialysis patients. Blood and 24 h urinary specimens were obtained from 79 consecutive chronic haemodialysis patients with a urinary output greater than 100 mL/day. Thirty-five patients with a glomerular filtration rate (GFR) ≥ 3.0 mL/min were included as group A, and 44 patients with GFR < 3.0 mL/min as group B. Additionally, the whole dialysed fluids during a session of haemodialysis were collected from another nine patients. Concentrations of phosphate, creatinine, urea nitrogen, intact parathyroid hormone (iPTH) and fibroblast growth factor 23 (FGF-23) U0126 mouse were measured. Twenty-four hour urinary phosphate excretion (UPE) was 283 ± 115 and 139 ± 57 mg/day (9.1 ± 3.5 and 4.5 ± 1.8 mmol/day) in groups A and B, respectively. Tubular reabsorption of phosphate (TRP) was 39.2 ± 13.3 and 31.7 ± 13.6% in groups A and B, respectively (P = 0.02). UPE significantly correlated with GFR (r = 0.85, P < 0.001) and PTH (r = 0.44, P < 0.001), but not with FGF-23, in the entire patient population. The correlation between UPE and intact PTH levels was absent in group B. Weekly UPE in group A was significantly greater (P < 0.001), while that in group B was similar to the amount of phosphate removed by a haemodialysis session.